Innovates and develops antibody-based therapeutics
Numab Therapeutics AG
Incorporated
14.06.2011Headquarters
HorgenSupport
Our proprietary platforms Lambda-Cap™ and MATCH™ are designed to create differentiated therapeutics on a repeatable basis. Using a novel, rational process, our discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first-generation antibody therapies in terms of potency, stability, effect duration, and safety. Alongside our own in-house pipeline programs we have a number of strong discovery and development partnerships with pharma and biotech.
News
Regulatory approval and a milestone payment for Swiss biotechs (startupticker.ch)
Four biotech startups reach key milestones (startupticker.ch)
Seasoned leaders step into key roles at life sciences startups (startupticker.ch)
Numab raises additional CHF50 million (startupticker.ch)
FDA approval and a key partnership to accelerate drug development (startupticker.ch)
Biotech companies report progress in clinical trials (startupticker.ch)
The most promising Swiss biotech startups and scale-ups of 2024, according to investors (TOP 100)
Numab Therapeutics' spin-off, Yellow Jersey Therapeutics, gets acquired by Johnson & Johnson for USD 1.25 billion (venturelab.swiss)
Johnson & Johnson acquires Numab spin-off for USD 1.25 billion (startupticker.ch)
Numab Therapeutics extends partnership with Ono Pharmaceutical (startupticker.ch)
Early-stage pharmaceutical companies make strides in cancer- and immunotherapy (startupticker.ch)
Numab TherapeutIcs doses first patient with eczema (startupticker.ch)
Numab signs a CHF 258 million deal with Ono Pharmaceuticles (startupticker.ch)
Numab Therapeutics completes oversubscribed CHF 100 million Series C financing (venturelab.swiss)
Numab Therapeutics Completes CHF 100 Million Series C Financing (startupticker.ch)
Numab Therapeutics signs co-development partnership with Japanese Pharma (startupticker.ch)
Startups win strong and well-connected board members (startupticker.ch)
Numab Therapeutics advances to the clinical trials stage (startupticker.ch)
Boehringer Ingelheim to Develop Antibody Therapeutics with Numab (startupticker.ch)
Numab Therapeutics to receive additIonal CHF 260M from its Japanese partner (startupticker.ch)
Milestones news
